- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00244764
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- GSK Investigational Site
-
Kogarah, New South Wales, Australia, 2217
- GSK Investigational Site
-
Randwick, New South Wales, Australia, 2031
- GSK Investigational Site
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- GSK Investigational Site
-
Footscay, Victoria, Australia, 3011
- GSK Investigational Site
-
Heidelberg, Victoria, Australia, 3084
- GSK Investigational Site
-
Parkville, Victoria, Australia, 3050
- GSK Investigational Site
-
-
-
-
-
Bruxelles, Bélgica, 1200
- GSK Investigational Site
-
Bruxelles, Bélgica, 1070
- GSK Investigational Site
-
Gent, Bélgica, 9000
- GSK Investigational Site
-
Jette, Bélgica, 1090
- GSK Investigational Site
-
Liège, Bélgica, 4000
- GSK Investigational Site
-
Roeselare, Bélgica, 8800
- GSK Investigational Site
-
Wilrijk, Bélgica, 2610
- GSK Investigational Site
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010-3000
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90095
- GSK Investigational Site
-
Orange, California, Estados Unidos, 92868
- GSK Investigational Site
-
San Francisco, California, Estados Unidos, 94115
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80010
- GSK Investigational Site
-
-
Georgia
-
Tucker, Georgia, Estados Unidos, 30084
- GSK Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- GSK Investigational Site
-
-
New York
-
New York, New York, Estados Unidos, 10032-3713
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- GSK Investigational Site
-
Cleveland, Ohio, Estados Unidos, 44195
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- GSK Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- GSK Investigational Site
-
Kowloon, Hong Kong
- GSK Investigational Site
-
Tuen Mun, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Haifa, Israel, 31096
- GSK Investigational Site
-
Petach Tikva, Israel, 49100
- GSK Investigational Site
-
Tel Aviv, Israel, 64239
- GSK Investigational Site
-
Zrifin, Israel, 70300
- GSK Investigational Site
-
-
-
-
-
Beijing, Porcelana, 100034
- GSK Investigational Site
-
Beijing, Porcelana, 100853
- GSK Investigational Site
-
Shanghai, Porcelana, 200040
- GSK Investigational Site
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510060
- GSK Investigational Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210029
- GSK Investigational Site
-
-
Shandong
-
Jinan, Shandong, Porcelana, 250012
- GSK Investigational Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310003
- GSK Investigational Site
-
-
-
-
-
Brno, República Checa, 656 53
- GSK Investigational Site
-
Hradec Kralove, República Checa, 500 05
- GSK Investigational Site
-
Praha 2, República Checa, 12808
- GSK Investigational Site
-
-
-
-
-
Taipei, Taiwán, 100
- GSK Investigational Site
-
Taipei, Taiwán
- GSK Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Histologically or cytologically confirmed diagnosis of Renal Cell Carcinoma of predominantly clear-cell histology (excluding chromophobe, papillary, collecting duct, and undifferentiated tumors) which is metastatic or locally recurrent
- Either no prior systemic therapy or failed only 1 prior cytokine-based or bevacizumab-based therapy
- Evidence of documented measurable disease by RECIST criteria
- Male or female at least 21 years of age
A woman is eligible to enter and participate in the study if she is of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who:
- Has had a hysterectomy,
- Has had a bilateral oophorectomy (ovariectomy),
- Has had a bilateral tubal ligation,
- Is post-menopausal (total cessation of menses for >= 1 year).
Childbearing potential, has a negative serum pregnancy test at Screening Period and serum or urine pregnancy test at Day1, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
- An intrauterine device (IUD) with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the clinical trial, and for at least 21 days after the last dose of investigational product.
- Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).
A man with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception (e.g. condom) or abstinence during the study and for 28 days following the last dose of investigational drug.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
- Adequate bone marrow function.
- Adequate hepatic function.
- Adequate renal function.
- Adequate PT/PTT or INR/aPTT.
- Able to swallow and retain oral medications.
- Written informed consent.
Exclusion criteria:
- Received prior non-cytokine or non-bevacizumab therapies .
- Received chemotherapy for renal cell carcinoma.
- Have had any major surgery, radiotherapy, or immunotherapy within the last 28 days and/or not recovered from prior therapy.
- History of hypercalcemia within two months of start of therapy.
- Patients who are pregnant or lactating.
- Poorly controlled hypertension.
- QTc prolongation defined as a QTc interval ≥ 480 msecs or other significant ECG abnormalities.
- Has Class II, III or IV heart failure as defined by the New York Heart Association functional classification system. A subject who has a history of Class II heart failure and is asymptomatic on treatment may be considered eligible.
- Any history of cerebrovascular accident [CVA].
- History of myocardial infarction, admission for unstable angina, cardiac angioplasty or stenting within the last 12 weeks.
- History of venous thrombosis in last 12 weeks.
- Current use of therapeutic warfarin.
- Use of antiplatelet agents other than aspirin (≤ 325 mg/day).
- Leptomeningeal or brain metastases.
- Prior history of malignancies other than renal cell carcinoma (except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or the subject has been free of any other malignancies for > 5 years).
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition (including lab abnormalities) that could interfere with subject safety or obtaining informed consent.
- History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism or excretion of study drugs. Has any unresolved bowel obstruction or diarrhea.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- Is on any specifically prohibited medication or requires any of these medications during treatment with GW786034.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Pazopanib
All patients receive GW786034.
At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug.
After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
|
All patients receive GW786034.
At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug.
After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
|
Comparador de placebos: Placebo
All patients receive GW786034.
At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug.
After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
|
All patients receive GW786034.
At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug.
After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall Response by RECIST Criteria
Periodo de tiempo: Baseline to Response (up to 2.40 years). Assessments occurred at Week 12 and every 8 weeks thereafter.
|
The overall response is the number of participants who experience a confirmed complete (CR) or partial response (PR) of the total analysis population.
Per the Response Evaluation Criteria In Solid Tumors (RECIST): CR = all detectable tumor has disappeared, PR = a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum, Progressive disease (PD) = a >=20% increase in target lesions, Stable Disease = small changes that do not meet previously given criteria.
|
Baseline to Response (up to 2.40 years). Assessments occurred at Week 12 and every 8 weeks thereafter.
|
Stable Disease at 12 Weeks - Interim Analysis of First 60 Participants
Periodo de tiempo: Week 12
|
The protocol called for an interim analysis of the first 60 participants to determine their status at Week 12, and to determine the number of participants with stable disease, although all categories were reported.
Stable disease is defined as a disease that has not grown enough to be called progressive disease and has not shrunk enough to be called partial/complete response.
|
Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Duration of Response
Periodo de tiempo: First response until progression of disease (up to 2.40 years). Assessments occurred at Week 12 and every 8 weeks thereafter.
|
Using RECIST criteria: date of first confirmed tumor response (CR or PR) to date of tumor progression or to death.
Participants who did not progress or die were censored at their last radiologic assessment.
Only participants who had a response were analyzed.
|
First response until progression of disease (up to 2.40 years). Assessments occurred at Week 12 and every 8 weeks thereafter.
|
Progression-free Survival
Periodo de tiempo: From the first day of treatment to the earliest date of disease progression or death due to any cause (up to 2.40 years)
|
Progression-free Survival is defined as the interval between the first day of treatment and the earliest date of disease progression or death due to any cause, whichever occurred first.
Progressive disease is defined as a >=20% increase in target lesions.
|
From the first day of treatment to the earliest date of disease progression or death due to any cause (up to 2.40 years)
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Bonate PL, Suttle AB. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2013 Jul;72(1):231-40. doi: 10.1007/s00280-013-2191-0. Epub 2013 May 29.
- Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2.
- Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011 Jun;54(6):1237-43. doi: 10.1016/j.jhep.2010.09.028. Epub 2011 Feb 12.
- Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer. 2010 Apr 27;102(9):1371-7. doi: 10.1038/sj.bjc.6605653. Epub 2010 Apr 13.
- Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C, Pandite L. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Eur J Cancer. 2016 Jan;53:96-104. doi: 10.1016/j.ejca.2015.10.006. Epub 2015 Dec 15.
- Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010 Jan 20;28(3):475-80. doi: 10.1200/JCO.2008.21.6994. Epub 2009 Dec 14.
- White AJ, LaGerche A, Toner GC, Whitbourn RJ. Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. Int J Cardiol. 2009 Jan 24;131(3):e92-4. doi: 10.1016/j.ijcard.2007.07.066. Epub 2007 Oct 24.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- VEG102616
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Carcinoma De Célula Renal
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and Kidney... y otros colaboradoresReclutamientoEnfermedades Renales Crónicas | Fallo renal agudo | Lesión renal aguda | Insuficiencia Renal Aguda | Insuficiencia renal cronica | Insuficiencia Renal, Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia renal aguda | Insuficiencia Renal Crónica | Enfermedades... y otras condicionesEstados Unidos
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillTerminadoEnfermedades Renales Crónicas | Enfermedad Renal Crónica Etapa 5 | Enfermedad Renal Crónica etapa 4 | Enfermedad renal pediátrica | Enfermedad Renal Crónica etapa 3 | Enfermedad Renal Crónica Etapa V | Enfermedad renal crónica, estadio IV (grave) | Enfermedad Renal Crónica Etapa 2 | Enfermedad Renal...Estados Unidos
-
University Hospital, BordeauxMinistry of Health, FranceTerminadoTrasplante Renal | Enfermedad renal crónica en etapa terminal | Insuficiencia Renal Aguda SeveraFrancia
-
Wake Forest University Health SciencesStanford UniversityTerminadoTrasplante Renal | Rechazo Renal Agudo | Rechazo Renal Crónico | Rechazo de Trasplante Renal | Sistema Renina-AngiotensinaEstados Unidos
-
Outset MedicalTerminadoLesión renal aguda | Enfermedad renal en etapa terminal (ESRD) | Enfermedad renal en etapa terminal en diálisisEstados Unidos
-
Novartis PharmaceuticalsTerminadoHemodiálisis | Terapia de reemplazo renal | Enfermedad renal en etapa terminal (ESRD) | Trasplante Renal | Enfermedad renal crónica (ERC)Alemania, Estados Unidos, Bélgica, Italia, España, Croacia, Taiwán, Australia, Austria, Grecia, Corea, república de, Líbano, Chequia, Israel, Países Bajos, Eslovenia, Suiza, Tailandia, Noruega, Pavo, Suecia, Argentina, Brasil, Japón, Serbia, Federación Rusa y más
-
Faculdade de Ciências Médicas da Santa Casa de...TerminadoEnfermedad Renal Crónica | Diálisis renalBrasil
-
ArdelyxAstraZenecaTerminadoEnfermedad renal en etapa terminal | ESRD | Enfermedad Renal Crónica Etapa 5Estados Unidos
-
European Society of Intensive Care MedicineTerminadoLesión renal aguda | Terapia de reemplazo renal | Enfermedad renal crónica en etapa terminalBélgica
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)TerminadoFallo renal agudo | Insuficiencia renal cronicaAustria
Ensayos clínicos sobre GW786034
-
Case Comprehensive Cancer CenterTerminadoCarcinoma de células renales de células claras | Cáncer de células renales en estadio III | Cáncer de células renales en estadio I | Cáncer de células renales en estadio IIEstados Unidos
-
National Cancer Institute (NCI)RetiradoSarcoma | Osteosarcoma | Tumor cerebral | Neuroblastoma | Tumor de WilmsEstados Unidos
-
GlaxoSmithKlineTerminadoCáncer de ovarios | Cáncer de trompa de Falopio | Cáncer peritoneal | Neoplasias De OvarioEstados Unidos, Australia, Singapur
-
Washington University School of MedicineNovartisTerminadoCáncer de pulmón de células no pequeñas | Cáncer de pulmón de células no pequeñas | Carcinoma de pulmón de células no pequeñasEstados Unidos
-
Illinois CancerCare, P.C.TerminadoCáncer de pulmón de células no pequeñasEstados Unidos
-
GlaxoSmithKlineTerminadoCarcinoma De Célula RenalEstados Unidos
-
GlaxoSmithKlineTerminadoCarcinoma De Célula RenalEstados Unidos
-
GlaxoSmithKlineTerminadoSarcoma De Tejido BlandoBélgica, Países Bajos, Reino Unido, Francia, Hungría
-
Illinois CancerCare, P.C.TerminadoCancer de prostataEstados Unidos
-
National Cancer Institute (NCI)TerminadoNeoplasias | LinfomaEstados Unidos